Genetic biomarkers in hypertrophic cardiomyopathy. (August 2013)

• Record Type: Journal Article
• Authors: Coats, Caroline J; Elliott, Perry M
• Is Part Of: Biomarkers in medicine. Volume 7:Number 4(2013)
• Page Start: 505
• Page End: 516
• Publication Date: 2013-08
• Subjects: biomarkers -- genetic counseling -- genetics -- hypertrophic cardiomyopathy; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm.13.79
• Languages: English
• ISSNs: 1752-0363

Abstract

Hypertrophic cardiomyopathy is a common inherited heart muscle disorder associated with sudden cardiac death, arrhythmias and heart failure. Genetic mutations can be identified in approximately 60% of patients; these are commonest in genes that encode proteins of the cardiac sarcomere. Similar to other Mendelian diseases these mutations are characterized by incomplete penetrance and variable clinical expression. Our knowledge of this genetic diversity is rapidly evolving as high-throughput DNA sequencing technology is now used to characterize an individual patient's disease. In addition, the genomic basis of several multisystem diseases associated with a hypertrophic cardiomyopathy phenotype has been elucidated. Genetic biomarkers can be helpful in making an accurate diagnosis and in identifying relatives at risk of developing the condition. In the clinical setting, genetic testing and genetic screening should be used pragmatically with appropriate counseling. Here we review the current role of genetic biomarkers in hypertrophic cardiomyopathy, highlight recent progress in the field and discuss future challenges.